(Q35162491)

6 August 2017

1 reference

title

Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents (English)

1 reference

6 August 2017

1 reference

Howard S Hochster

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

International Journal of Radiation Oncology Biology Physics

6 August 2017

published in

1 reference

6 August 2017

volume

56

1 reference

6 August 2017

issue

4 Suppl

1 reference

6 August 2017

page(s)

24-30

1 reference

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

ZD1839 (Iressa) in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900447-4

7 January 2021

10.1016/S0360-3016(03)00447-4

Identifiers

DOI

1 reference

6 August 2017

1 reference